Table 3 Diagnostic yield of methylation, cytology, and histology analyses in different subgroups of LC
Tumor Classification | Bronchoscopy | ||||||
|---|---|---|---|---|---|---|---|
Exfoliated cell BALF samples | Biopsy Histology + | Combined results | |||||
SHOX2 + | RASSF1A + | LungMe® + | Cytology + | ||||
n (%) | n (%) | n (%) | n (%) | n (%) | |||
Histology subtype | |||||||
LUAC | (n = 104) | 70 (67.3) | 48 (46.2) | 85 (81.7) | 31 (29.8) | 60 (57.7) | 99 (95.2) |
LUSC | (n = 53) | 49 (92.5) | 18 (34.0) | 50 (94.3) | 16 (30.2) | 38 (71.7) | 53 (100.0) |
SCLC | (n = 23) | 22 (95.7) | 16 (69.6) | 22 (95.7) | 8 (34.8) | 14 (60.9) | 22 (95.7) |
Metastatic Cancer | (n = 5) | 4 (80.0) | 3 (60.0) | 5 (100.0) | 1 (20.0) | 3 (60.0) | 5 (100.0) |
Total | (n = 185) | 145 (78.4) | 85 (45.9) | 162 (87.6) | 56 (30.3) | 115 (62.2) | 179 (96.8) |
Nodule location | |||||||
Central | (n = 46) | 43 (93.5) | 23 (50.0) | 43 (93.5) | 13 (28.3) | 27 (58.7) | 45 (97.8) |
Peripheral | (n = 127) | 95 (74.8) | 55 (43.3) | 108 (85.0) | 39 (30.7) | 82 (64.6) | 122 (96.1) |
Pathologic staging | |||||||
I | (n = 28) | 22 (78.6) | 8 (28.6) | 22 (78.6) | 7 (25.0) | 12 (42.9) | 25 (89.3) |
II | (n = 20) | 15 (75.0) | 8 (40.0) | 17 (85.0) | 5 (25.0) | 10 (50.0) | 19 (95.0) |
III | (n = 40) | 36 (90.0) | 18 (45.0) | 29 (92.5) | 10 (25.0) | 29 (72.5) | 39 (97.5) |
IV | (n = 97) | 75 (77.3) | 50 (51.5) | 85 (87.6) | 34 (35.1) | 64 (66.0) | 94 (96.9) |
Largest diameter | |||||||
0 ~ 10 mm | (n = 10) | 6 (60.0) | 2 (20.0) | 7 (70.0) | 2 (20.0) | 8 (80.0) | 8 (80.0) |
11 ~ 50 mm | (n = 124) | 89 (71.8) | 51 (41.1) | 102 (82.3) | 39 (31.5) | 79 (63.7) | 119 (96.0) |
51 ~ 100 mm | (n = 29) | 27 (93.1) | 16 (55.2) | 27 (93.1) | 10 (34.5) | 16 (55.2) | 29 (100.0) |
101 ~ 300 mm | (n = 12) | 12 (100.0) | 9 (75.0) | 12 (100.0) | 2 (16.7) | 8 (66.7) | 12 (100.0) |